Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production, has signed a license agreement with GSK, a leader in biopharmaceutical innovation, that grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products. The license will enable GSK to access the technology for rapid and scalable GMP production of DNA, with the potential to accelerate the production of multivalent mRNA ...